INTRODUCTION
Thyroid function in term newborns is characterized by an immediate postnatal increase in thyroid-stimulating hormone (TSH) followed by increases in triiodothyronine (T 3 ) and thyroxine (T 4 ). Infants born prematurely have lower levels of thyroid hormones relative to term newborns. 1, 2 The reasons for the hypothyroxinemia of the preterm newborn are numerous. The normal TSH and T 4 responses to thyrotropin-releasing hormone (TRH) in premature newborns implies an inherent deficiency of endogenous TRH as the etiology for their relative hypothyroxinemic state. No information is available concerning placental passage of thyroid hormone between 25 and 30 weeks' gestation, but hypothyroxinemia may be partly the result of the premature termination of maternal thyroid hormone transfer and placental TRH. In addition, nonthyroidal illness common in premature newborns such as undernutrition, respiratory distress, metabolic alterations and infections, are linked to low serum thyroid hormone levels. 2 Because thyroid hormones have important maturational effects on multiple organ systems. 3 ± 5 many investigations have examined the links between thyroid hormone levels and premature newborn outcomes. In 1983, a prospective collaborative study of preterm and small for gestational age infants was conducted in the Netherlands. 6 In 724 non±thyroid-hormone-supplemented infants under 32 weeks' gestation, there was a significant association between low T 4 7, 8 Clinical trials of postnatal T 4 supplementation had been conducted before this study. Thyroid hormone replacement did not increase mortality or compromise development in these studies, but also did not reduce preterm newborn morbidity. 9, 10 However, interpretation of these data was confounded because of the dosing regimens and length of treatment employed. Furthermore, Ballard et al. 11 reported in 1992 that maternal administration of TRH (with transplacental transfer to the fetus) reduced the incidence of chronic lung disease in preterm newborns when used in combination with glucocorticoids. These promising TRH findings, and our recognition that all studies attempting to augment thyroid hormone levels in the premature newborn had been conducted in an era before surfactant replacement, prompted us to reexamine the question in a randomized, placebo-controlled double-blind trial of T 4 administration in preterm infants, the majority of whom
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Transient hypothyroxinemia in premature newborns has been linked with poor neonatal outcomes. We designed this study to evaluate the effects of early thyroxine ( T 4 ) administration in the premature infant.
STUDY DESIGN:
A total of 49 newborns less than 32 weeks' gestation, were randomized in a double -blind, placebo -controlled trial. Within the first 48 hours of life, T 4 ( 10 or 20 g / kg; intravenous or through nasogastric tube, respectively ) was administered for a total of 21 days. Chronic lung disease, the primary outcome variable, was defined by oxygen dependency at 28 days of life.
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received surfactant replacement therapy. We hypothesized that neonatal pulmonary complications would decrease with early neonatal T 4 supplementation. If these postnatal T 4 doses could be shown to be safe, supplementation could be given to infants who delivered too precipitously to receive benefit from antenatal attempts to augment fetal maturation.
MATERIALS AND METHODS Subject Selection
Following approval by the Human Subjects' Committee, a total of 49 infants less than 32 weeks' gestation with birth weights of 600 to 1500 gm were studied at the Harbor-UCLA and Martin Luther King/Drew Medical Centers. Gestational age was determined by maternal history and/or prenatal ultrasound dating. When reliable prenatal information was unavailable, gestation was estimated by physical and neurologic assessment using the Ballard score. Maternal thyroid disease or maternal use of antithyroidal medicines or illicit drugs excluded infants from participation in the study. Infants with lethal malformations or primary congenital hypothyroidism were also excluded. If a twin birth occurred, only the firstborn was randomized. The incidence of parental refusal was 38%.
Patients were randomized separately with regard to hospital of origin, sex, and birth weight. To assure balanced groups, subjects were randomized in blocks of eight, and separate assignment tables were developed for each of the subgroups described above. The biostatistician (N. B.) prepared a box of sequentially numbered, sealed envelopes for each subgroup containing the treatment assignment. Randomization was achieved by selecting the next envelope from the appropriate box when an infant entered the study.
Treatment Protocol
Parental consent, randomization, and initiation of treatment were accomplished within 48 hours of birth. All neonatal care decisions, including antenatal glucocorticoid treatment, oxygen titration, and weaning and surfactant replacement therapy (Survanta, Abbott Laboratories), were determined by attending physicians blinded to the study. Research nurses maintained detailed records on all infants for evaluation of side effects on an ongoing basis. The results were reviewed twice yearly by the Data and Safety Monitoring Committee.
Infants received intravenous T 4 (10 g/kg per day once daily) or placebo beginning within 48 hours of birth. Levothyroxine sodium was lyophilized with 10 mg of mannitol and 0.7 mg of anhydrous tribasic sodium phosphate, dissolved in 0.9% NaCl solution, and infused over 3 minutes immediately after preparation. The placebo solution was 0.9% NaCl. Oral T 4 (20 g/kg per day once daily) was administered as soon as oral feedings were begun. The T 4 (n=29) and placebo (n=22) preparations were of similar color and consistency and were given in identical volumes per body weight for a total of 21 days. The initial 10 infants were observed every 15 minutes for 2 hours following administration for adverse reactions (e.g., hyperthermia, tachycardia); no untoward effects were noted. Throughout the study course, iodine-containing solutions were avoided.
Cord blood samples were collected for measurements of free T 4 and TSH concentrations on all infants potentially eligible for study. Free T 4 and TSH concentrations were measured again upon enrollment (immediately before the first intravenous dose of agent) and weekly for 4 weeks. These values were reported to one of the authors (J. A. B.) for review and action if needed. Results also were monitored by the Data and Safety Monitoring Committee. In addition, newborns were tested within 1 to 2 days after birth by the California State Newborn Screening program to detect congenital hypothyroidism, eliminating the possibility of missing an infant requiring T 4 therapy by our sample batching procedure. The screening filter paper samples were obtained by the research nurses before T 4 or placebo was administered. Total blood removal for the entire study was less than 5 ml.
TSH and free T 4 levels were determined on all samples using RIA kits obtained from Wallac Inc. (Gaithersburg, MD) in the General Clinical Research Center Core Laboratory. Sensitivity and intra-and interassay coefficients of variation for the TSH assay were 0.25 U/ml, 4.7% and 8.4%, respectively. Values for the free T 4 assay were 0.28 ng/dl, 5.7% and 13%, respectively. Assay sample volumes were adjusted to give results in the linear range of the assays.
Outcomes and Analysis
The primary outcome of this trial was the need for oxygen therapy on day of life 28. Secondary outcome information including death before 12 months, intraventricular hemorrhage, periventricular leukomalacia, patent ductus arteriosus, sepsis, and necrotizing enterocolitis were recorded on all enrolled infants. Analysis was done on an intent-to-treat basis, so that patients who died before 28 days of life were considered failures, whether T 4 -or placebo-treated.
The study design specified a final sample size of 150 subjects per group to have 80% power to detect a reduction in oxygen requirement at 28 days of life from 30% on placebo to 15% on T 4 , using a one-sided test. The design also specified an interim analysis after 1 year of data collection to check for outstanding effects and to determine if the power estimates were accurate.
Data are expressed as either meanSEM or as a percentage. Statistical significance was accepted at p<0.05 using chi-square analysis or t-test as appropriate.
RESULTS
There were 29 infants entered in the T 4 -treatment group and 20 in the placebo group. One infant in the control group was removed after Smith et al.
Early Thyroxine Supplementation in Preterm Infants enrollment into the study following diagnosis of congenital hypothyroidism and one was discovered to be >32 weeks' gestation. Three infants died in the placebo group and two in the T 4 -treated group. The interim analysis showed almost equal rates of success for our primary endpoint, oxygen requirement at 28 days of life. A power analysis indicated that thousands of subjects per group would be required to have 80% power to detect this difference. Therefore, the study was terminated and the 1-year data are presented. Gestational age, birth weight, Apgar scores, male/female ratio, and incidence of antenatal glucocorticoid exposure were not different between the T 4 -treated and placebo groups (Table 1) . Serum free T 4 concentrations were similar in the treatment and placebo groups before T 4 administration (Figure 1) . The treatment group manifested significantly higher free T 4 levels throughout the 21-day study period. One week following cessation of T 4 treatment, the free T 4 levels in the treated group had fallen to levels comparable to the placebo infants. Figure 1 shows TSH levels were detectable in nearly all subjects at the time of enrollment in the study. During the 21-day treatment period, the majority of T 4 -treated infants had undetectable serum TSH levels. One week following cessation of T 4 treatment, serum TSH was detectable in all except two infants. Free T 4 and TSH levels in cord blood tended to be lower in the smaller infants ( <1200 gm), but these differences did not reach statistical significance ( Table 2 ). The incidence of surfactant administration was comparable in the T 4 -treated and control groups (34% vs. 41%, respectively). There were no differences in the percent of infants requiring oxygen at 28 days of life in the T 4 and placebo groups ( Table 3 ). The number of ventilation days trended lower in the treated group, but was not found to be significantly different.
Mortality rates were comparable (7% vs. 14%) in the T 4 -treated versus placebo group (Table 4) . Two infants died in the T 4 -treated group (birth weights=700 and 753 gm) and three infants in the placebo group died (birth weights=1085, 1086, and 633 gm). The incidence of grade III and IV intraventricular hemorrhage, periventricular leukomalacia, patent ductus arteriosus, and sepsis were comparable in the placebo and T 4 -treated groups (Table 4) . No differences in complications or mortality were found between the two centers delivering neonatal care to the patients.
DISCUSSION
Despite improvements in neonatal care, respiratory distress syndrome, and chronic lung disease remain significant causes of morbidity in premature infants. Because premature newborns are hypothyroxinemic in the early neonatal period relative to term newborns, and thyroid hormone has been shown to induce pulmonary maturation in laboratory models, 4 we designed this study to determine whether early postnatal administration of T 4 would decrease neonatal pulmonary morbidity. We also evaluated the incidence of common complications of the preterm newborn as secondary outcomes. Despite trends toward improved function, we did not observe a significant difference in the incidence of pulmonary morbidity associated with postnatal T 4 supplementation. T 4 therapy also had no effect on morbidity or mortality associated with preterm delivery.
Because of the reported association between hypothyroxinemia and neonatal mortality in epidemiologic studies, there has been an increased focus on antenatal effects of thyroid hormones. Intra-amniotic T 4 injection has been shown to increase the lecithin to sphingomyelin ratio in amniotic fluid of preterm pregnancies. 13, 14 These latter clinical trials were conducted after the availability of surfactant replacement therapy, which may account for the lack of TRH-induced improvement in pulmonary outcome.
Therapies designed to induce fetal pulmonary maturation prenatally require an interval of time from treatment to delivery to be effective. Because some threatened preterm deliveries cannot be delayed, postnatal interventions are an attractive alternative to antenatal therapy. At the time we initiated the present study, trials of T 4 supplementation had been conducted with conflicting results. Amato et al. 9 treated 18 premature infants with respiratory distress syndrome with two doses of intravenous T 4 administered at 1 and 24 hours of age. The infants receiving T 4 showed no improvement in pulmonary outcome relative to the control group. A double-blind study of 23 infants, 26 to 28 weeks' gestation, receiving daily T 4 supplementation beginning in the second week of life, found no differences in pulmonary outcome. 10 However, these studies were less than definitive because of the dosing regimens chosen and because they were conducted in the presurfactant era.
Our findings that postnatal T 4 therapy does not improve pulmonary outcome in the preterm newborn are consistent with results of a recent study by Vanhole et al. 15 who assessed the efficacy of 2 weeks of T 4 studied the effects of 6 weeks of postnatal T 4 supplementation of some 200 very low birth weight infants. Although pulmonary morbidity was not the primary outcome measure of the study, they found no differences in the prevalence of chronic lung disease in treated and nontreated infants.
There are several possible explanations for the lack of improvement in pulmonary outcome following postnatal T 4 supplementation in the premature newborn. We chose a T 4 dose that increased the T 4 and suppressed TSH concentrations for the 21-day treatment period. However, preterm infants may be relatively T 4 insensitive at the gestational ages studied. As mentioned previously, the earlier studies suggesting pulmonary improvement with thyroid supplementation were conducted before the era of surfactant replacement. Because much of the pulmonary morbidity associated with prematurity is related to surfactant deficiency, T 4 supplementation may have less impact on premature newborns receiving exogenous surfactant.
Recent retrospective epidemiologic studies suggest links between severe hypothyroxinemia in the preterm newborn and an increased risk for intraventricular hemorrhage and death, 16 as well as abnormal neurologic development. 7, 8, 17 The significance of these results is compromised by the fact that thyroid function was inferred from a single measurement of total T 4 (from filter paper samples collected for newborn thyroid screening), which usually is decreased in association with perinatal morbidity. Our prospective, doubleblind T 4 treatment study, in contrast, showed no effect of prolonged increases in T 4 concentration on mortality, intraventricular hemorrhage or periventricular leukomalacia, in agreement with the well-controlled prospective study of van Wassenaer et al. These investigators also assessed the treatment effect on 24-month mental development outcome and found no statistically significant difference in the neurologic outcome of those infants receiving postnatal T 4 versus placebo. 18 In summary, we found that, contrary to our hypothesis, early postnatal T 4 supplementation did not improve pulmonary outcome or decrease the incidence of mortality in preterm infants receiving surfactant replacement therapy. These results are consistent with other recent studies of antenatal TRH and postnatal T 4 treatment studies. Thus, our data, combined with the findings of others, suggest that although we observed no negative consequences of thyroid supplementation, other strategies to reduce morbidity and mortality in the premature newborn should be pursued.
